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Epidemiology of Cryptococcosis and Cryptococcal 
Meningitis in a Large Retrospective Cohort of Patients 
After Solid Organ Transplantation
Ige A. George,1 Carlos A. Q. Santos,1,a Margaret A. Olsen,1,2 and William G. Powderly1
Divisions of 1Infectious Diseases and 2Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri
Background. Cryptococcosis is the third most common invasive fungal infection in solid organ transplant (SOT) recipients. 
There are no nationally representative data describing the incidence, risk factors, and outcomes of cryptococcosis after SOT.
Methods. We assembled a large cohort of adult SOT recipients using Classification of Diseases, Ninth Revision, Clinical Modification 
billing data from Healthcare Cost and Utilization Project State Inpatient Databases of Florida (2006–2012), New York (2006–2011), 
and California (2004–2010). Demographics, comorbidities, death, and cryptococcal infections coded during hospitalization were 
identified.
Results. A total of 42 634 adults with SOT were identified during the study period. Cryptococcal disease was identified in 0.37% 
(n = 158), 44% of which had meningitis (n = 69). Median time to diagnosis of cryptococcosis was 464 days (range, 4–2393). The 
median time to onset of cryptococcosis was earlier for lung (191 days; range, 7.5–1816), heart (195 days; range, 4–1061), and liver 
(200 days; range, 4–1581) compared with kidney transplant recipients (616 days; range, 12–2393; P < .001, log rank test). Very ear-
ly-onset disease (<30 days after transplantation) more frequently occurred in liver and lung transplant recipients. Lung transplant 
recipients had the highest risk of cryptococcosis (hazard ratio [HR], 2.10; 95% confidence interval [CI], 1.21–3.60). Cryptococcosis 
was associated with death (HR, 2.29; 95% CI, 1.68–3.11), after adjusting for age, type of SOT, and other comorbidities.
Conclusions. Cryptococcosis is rare after SOT, but it is associated with significantly increased risk of death. Lung transplant recip-
ients are at highest risk for cryptococcosis among SOTs. Nonkidney transplants have earlier onset of cryptococcosis and higher risk 
of death compared with kidney transplant recipients.
Keywords. cryptococcosis; epidemiology; outcomes; solid organ transplant.
Cryptococcosis is an important opportunistic fungal infection 
that causes significant mortality and morbidity among solid 
organ transplant (SOT) recipients [1–3]. Traditionally, crypto-
coccosis is most often associated with human immunodeficiency 
virus (HIV) infection; however, with the advent of effective 
antiretroviral therapy, the majority of cases in developed nations 
occur among non-HIV-infected patients, especially organ trans-
plant recipients [4, 5]. Among 302 cases of cryptococcosis iden-
tified over a 14-year period from an academic medical center in 
the southern United States, 28% occurred in SOT recipients [4]. 
Results from the Transplant-Associated Infection Surveillance 
Network (TRANSNET), a consortium of 23 US transplant 
centers, showed that cryptococcosis is the third most common 
invasive fungal infection in SOT recipients, after invasive can-
didiasis and aspergillosis, comprising 8%–10% of all invasive 
fungal infections identified in SOT recipients [1, 6]. Overall inci-
dence rates of cryptococcosis in cohorts of SOT recipients range 
from 0.2% to 4.1%, depending on the type of organ transplanted 
and the duration of follow-up, and has remained stable over the 
years [1, 3]. Mortality rates among all types of SOT recipients 
with cryptococcosis range from 14% to 19.6% and may approach 
50% in recipients with meningitis [3, 6, 7].
Studies from academic medical centers contribute to our 
understanding of epidemiology of cryptococcosis and its out-
comes in SOT recipients; however, they have limited generaliz-
ability. Cryptococcosis identified and managed in community 
hospitals after patients have transitioned away from transplant 
centers may have been missed, especially with the prolonged 
time to onset after transplant. There are no population-level 
data describing the epidemiology of cryptococcosis and cryp-
tococcal meningitis posttransplantation. We assembled a large 
and more representative cohort of SOT recipients from multiple 
hospitals using the longitudinal Agency for Healthcare Research 
and Quality (AHRQ), Healthcare Cost and Utilization Project 
State Inpatient Databases (SID) to study the epidemiology of 
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cryptococcosis and cryptococcal meningitis. The SID contain 
demographic and billing data that capture inpatient diagnoses 
and procedures through International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) coding. This 
approach allowed us to follow a large number of patients over a 
long period of time and identify cryptococcosis and cryptococ-
cal meningitis regardless of whether patients were treated in the 
index transplant hospital or a different hospital.
METHODS
Study Design and Patient Population
We performed a retrospective cohort study of adults aged 
18  years and older who underwent kidney, lung, liver, heart, 
pancreas, or intestine SOT, identified by ICD-9-CM proce-
dure codes (55.69, 50.59, 37.51, 33.50, 33.51, 33.52, 33.6, 52.80, 
52.86, 46.97) from 2004 to 2010 in California, 2006 to 2012 in 
Florida, and 2006 to 2011 in New York. These states and years 
were chosen based on the availability of patient-level encrypted 
identifiers to link admissions within and across hospitals over 
time and the population diversity of these states. We chose the 
cohort inception years to allow 1 year of prior data to identify 
comorbidities. Only the first transplant during the study period 
was included for all patients. We excluded patients who (1) 
lived in states other than the one where transplantation was 
performed, (2) were coded for cryptococcosis and cryptococcal 
meningitis within 1 year before transplantation, or (3) died on 
the day of transplant. This study was considered exempt by the 
Washington University School of Medicine Human Research 
Protection Office.
Demographic Data, Comorbidities, and Follow-up
Demographic characteristics of the study population were 
determined during the transplant admission. Comorbidities 
were identified using the Elixhauser classification and ICD-
9-CM diagnosis codes within 1  year before and during the 
transplant hospitalization [8]. Comorbidities that were the 
primary reason leading to transplant were excluded (eg, renal 
failure in kidney transplant, liver disease in liver transplants). 
Transplant failure or rejection episodes were identified during 
readmissions but considered a potential risk factor for cryp-
tococcosis only if it was identified before its onset. Inpatient 
readmissions were identified using the encrypted patient-level 
identifier. Dates of onset of cryptococcosis, cryptococcal men-
ingitis, and transplant failure or rejections were estimated to 
be midpoint of the stay if they were coded during the initial 
transplant hospitalization. For events identified during read-
missions, the date of admission was considered the date of 
onset. Prior transplantation was identified by a procedure code 
for SOT in the year before transplantation (only in the year 
reserved for comorbidities) or by a V-code to indicate prior 
transplant (V42.0, V42.7, V42.1, V42.6, V42.83, and V42.84). 
Transplant failure or rejection was not considered if it was 
coded during the transplant hospitalization in an individual 
with a history of SOT. Outcomes identified during the SOT 
hospitalization and during hospital readmissions were newly 
coded cryptococcosis (ICD-9-CM diagnosis code 117.5) and 
cryptococcal meningitis (ICD-9-CM diagnosis code 321.0). 
The ICD-9-CM diagnosis codes for septicemia, pneumonia, 
surgical site, and skin and soft tissue infection assigned dur-
ing the admission coded for cryptococcosis were used to char-
acterize the site of cryptococcal infection (codes listed in the 
Supplementary Material).
Statistical Analysis
Descriptive statistics were used to describe the demographic 
and clinical characteristics of the study population. Potential 
risk factors for cryptococcosis and inpatient death were ana-
lyzed using univariable and multivariable Cox proportional 
hazards models. To create a censor date, the transplant date 
was estimated as (1) the 15th day of the admission month for 
California and New York and (2) the midpoint of the discharge 
quarter for Florida (Florida SID does not provide an admission 
month). In the risk factor analysis for cryptococcosis, patients 
were censored at inpatient death or maximum follow-up. The 
proportional hazards assumption was evaluated for each vari-
able using visual inspection of log-log survival curves and the 
correlation between Schoenfeld residuals and ranking of indi-
vidual failure times [9]. Variables were specified by selecting 
clinically meaningful factors that could potentially be associ-
ated with cryptococcosis, and we sequentially eliminated vari-
ables with highest P values to arrive at a parsimonious model, 
followed by assessment of confounding to arrive at the final 
model. To evaluate whether the risk of death with and without 
cryptococcosis varied with time, we used a heavy-side function 
to assess differential risk within 1 year and after 1 year of trans-
plant [10]. Statistical significance was set at P < .05. All analyses 




The final study population consisted of 42 634 adult SOT recip-
ients. A total of 63.7% had kidney transplantation, followed by 
21.1% liver, 7.2% heart, and 5.2% lung transplants. Other or 
multiple organs were transplanted in 2.4% of the SOT patients 
(pancreas, intestine, or multiorgan). The mean age at the time of 
transplant was 51.7 years; 62.6% were males, 51.2% were white, 
21.1% were Hispanic, 76.3% lived in large metropolitan areas, 
and 15.8% had Medicaid or self-pay listed as primary insurance. 
Commonly identified comorbidities were as follows: diabetes 
mellitus (37.5%), renal failure (12.0 %), and chronic lung dis-
ease (10.1%). A total of 1492 patients (3.5%) had history of a 
prior organ transplant(s). The median duration of follow-up 
after SOT was 1295 days (range, 1–3075 days).
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Cryptococcal Infections
One hundred fifty-eight patients were coded for cryptococco-
sis (0.37%) after SOT. There was no significant difference in 
the incidence of cryptococcosis identified between the 3 states 
(0.35% in California, 0.37% in Florida, and 0.41% in New York; 
P = .661). Sixteen of 158 patients were coded for cryptococcosis 
during the index transplant hospitalization. A total of 69 (44%) 
patients were identified with meningitis. Of the remaining 
patients with nonmeningeal cryptococcosis, 41 (46.06%) were 
coded for pneumonia and 19 (21.34%) additional patients were 
coded for septicemia, skin and soft tissue, or surgical site infec-
tion. Eighty-nine (0.32%) patients with cryptococcosis were 
identified after kidney transplant, 40 (0.44%) after liver trans-
plant, 15 (0.66%) after lung transplant, and 13 (0.42%) after 
heart transplantation. Twenty-six percent (38 of 158) of patients 
with cryptococcosis identified at readmission were treated at a 
hospital different from the index transplant surgery hospital. 
Eighty-three percent (57 of 69)  of patients with cryptococcal 
meningitis had a procedure code for a lumbar puncture during 
the admission compared with 41% (36 of 89) of patients coded 
for cryptococcosis without meningitis (P < .001).
Lung transplant recipients had the highest risk of crypto-
coccosis compared with other organ transplant recipients, 
with a hazard ratio (HR) of 2.10 after adjusting for age and 
underlying comorbidities (Table 1). Increasing age, diabetes, 
and having Medicaid or no health insurance were also risk 
factors for cryptococcosis in the multivariable Cox model 
(Table 2).
Table 1. Univariable Risk Factors for Cryptococcosis in Patients with and without Cryptococcosis among 42 634 Solid Organ Transplant Recipients
Risk Factor
No. (%) of Patients
HR (95% CI) P ValueWith Cryptococcosis (n = 158) Without Cryptococcosis (n = 42 476)
Age
 18–40 years 16 (10.1) 8456 (19.9) 1
 41–50 years 35 (22.2) 8925 (21.0) 2.07 (1.14–3.74) .016
 51–60 years 50 (31.6) 13 119 (30.9) 2.04 (1.16–3.58) .013
 60–70 years 48 (30.4) 9969 (23.5) 2.67 (1.52–4.71) .007
 >70 years <11 2007 (4.7) 2.50 (1.10–5.65) .028
Race
 White 74 (46.8) 20 926 (49.3) 1
 Black 17 (10.7) 6363 (14.9) 0.78 (0.46–1.34) .359
 Hispanic 42 (26.6) 8981 (21.1) 1.36 (0.93–1.98) .114
 Asian or Pacific Islander 13 (8.2) 3364 (7.9) 1.11 (0.62– 2.02) .728
 Other or missing 12 (7.6) 2842 (6.7) 1.31 (0.71–2.42) .382
Female sex 54 (34.1) 15 882 (37.4) 0.95 (0.89–1.01) .596
Type of Insurance
 Private/Medicare/Others 133 (84.2) 38 489 (90.6) 1
 Medicaid/Self-pay 25 (15.8) 3987 (9.4) 1.80 (1.17–2.75) .007
Income Quartile
 0–25th 73 (46.2) 13 081 (30.8) 2.10 (1.30–3.33) .002
 26–50th 35 (22.1) 9367 (22.0) 1.54 (0.91–2.58) .105
 51–75th 26 (16.5) 10 115 (23.8) 1.05 (0.60–1.83) .857
 76–100th 24 (15.2) 9913 (23.3) 1
Type of Transplant
 Kidney 89 (56.3) 27 129 (63.9) 1
 Liver 40 (25.3) 8970 (21.1) 1.32 (0.91–1.92) .142
 Lung 15 (9.5) 2223 (5.2) 2.06 (1.19–3.57) .009
 Heart 13 (8.2) 3059 (7.2) 1.29 (0.72–2.30) .397
 Others (multiorgan) <11 1095 (2.6) 0.27 (0.04–1.93) .191
Prior transplant failure/rejection 85 (53.8) 22 475 (52.9) 0.50 (0.16–1.59) .244
Other Comorbidities
 Diabetes mellitus  86 (54.4) 15 898 (37.4) 2.03 (1.48–2.78) .001
 Renal failure 16 (10.1) 5110 (12.0) 0.84 (0.52–1.41) .512
 Chronic pulmonary disease 19 (12.0) 4308 (10.1) 1.20 (0.74–1.93) .421
 Congestive heart failure 16 (10.1) 4127 (9.7) 1.02 (0.63–1.71) .930
 Liver disease 10 (6.3) 2243 (5.3) 1.22 (0.65–2.33) .532
 Connective tissue disorder <11 1923 (4.5) 0.56 (0.20–1.51) .252
 Prior transplantation <11 1489 (3.5) 0.51 (0.16–1.59) .243
Abbreviations: CI, confidence interval; HR, hazard ratio.
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The median time to diagnosis of cryptococcosis from the 
date of transplant was 464  days (range, 4–2393). The median 
time to onset of disease was earlier after lung (191 days; range, 
7.5–1816), heart (195 days; range, 4–1061), and liver (200 days; 
range, 4–1581) transplant than kidney transplant (616  days; 
range, 12–2393) (P < .001, Kruskal-Wallis test) (Figure 1).
Very Early Versus Later Onset Cryptococcosis
Very early-onset disease (cryptococcosis occurring within 30 days 
after transplantation) developed in 16 (10.1%) of 158 patients 
(median 10.7  days; range, 4–23) after transplant, whereas later 
onset cryptococcosis more than 30 days after transplant occurred 
in the remaining 142 patients (median 515 days; range, 32–2393). 
The proportion of patients with very early-onset disease among 
liver or lung transplants was significantly higher than other 
transplants (P < .001, Fisher’s exact test). However, inpatient mor-
tality did not differ between the patients with very early-onset ver-
sus later-onset cryptococcosis (P = 1.000, Fisher’s exact test).
Inpatient Mortality in Patients with Cryptococcosis
Forty-one of 158 (26.0%) patients with cryptococcosis died 
during the study period in-hospital versus 3879 of 42 476 
(9.1%) without cryptococcosis (HR, 2.57; P <  .001) (Table 3 
and Figure 2). Eighteen of 69 (26.1%) patients with crypto-
coccal meningitis died (HR 2.54, P  <  .001, compared with 
uninfected SOT recipients). In multivariable analysis, cryp-
tococcosis was associated with a 2.3-fold increased risk of 
inpatient mortality (P < .001), adjusting for age, type of trans-
plant, prior graft rejection or failure, and several comorbid-
ities (Table  3). There was no increased mortality risk with 
cryptococcosis during the first year after transplant (HR, 
1.39; P =  .257); however, there was a 3.2-fold increased risk 
of mortality more than 1  year after transplant (P  <  .001) 
(Figure 2). The risk of death was highest for lung, followed 
by liver, heart, and other transplants compared with renal 
transplant. Increasing age, prior transplant failure or rejec-
tion, congestive heart failure, liver disease, having Medicaid 
or no health insurance, and several other comorbidities were 
independent risk factors for in-hospital death (Table 3). The 
median time to death from diagnosis of cryptococcosis was 
87.5  days (range, 3–2792). The median time to death from 
transplant was 637  days (range, 32–2807) in patients with 
cryptococcosis and 359 days (range, 1–2858) in patients with-
out cryptococcosis (P < .001, log rank test).
DISCUSSION
We found that cryptococcal infections were rare but associated 
with significant mortality in a large diverse population of SOT 
recipients from 3 US states. The overall incidence of crypto-
coccosis was 0.37%, similar to the 12-month incidence of 0.2% 
reported in the TRANSNET study [1]. Prior studies have found 
that 44%–60% of SOT recipients with cryptococcosis developed 
central nervous system (CNS) involvement [2, 11, 12]. We found 
that meningitis was coded in 44% of the SOT recipients with cryp-
tococcosis. The Infectious Diseases Society of America guide-
lines recommend evaluating for meningitis by lumbar puncture 
in SOT recipients with positive cryptococcal antigen test and in 
all immunosuppressed patients with pulmonary cryptococcosis 
[13]. The proportion of patients coded for a lumbar puncture 
was significantly lower among the patients with cryptococcosis 
without meningitis compared with those patients coded for cryp-
tococcal meningitis. The slightly higher proportion of patients 
without cryptococcal meningitis when compared with previous 
studies could be due to (1) an error in additional coding for men-
ingitis or (2) an error in ascertainment, wherein an active search 
for CNS disease was not done in these patients [2, 11]. Among 



































Figure 1. Time to onset of cryptococcosis in days, stratified by type of transplant. 
Boxes represent 25th–75th percentile values (interquartile range [IQR]), and hori-
zontal lines represent the median and the diamonds the mean values.  Error bars 
indicate the maximum and minimum observation below the  upper and lower fences 
(1.5 IQR) and circles the maximum observations.
Table 2. Multivariable Cox Proportional Hazard Model of Risk Factors for 
Cryptococcosis
Risk Factor HR (95% CI) P Value
Age
 18–40 years 1.00
 41–50 years 1.92 (1.06–3.48) .030
 51–60 years 1.78 (1.01–3.13) .046
 60–70 years 2.28 (1.22–3.86) .007
 >70 years 2.41 (1.03–4.95) .041
Type of Transplant
 Kidney 1.00
 Liver 1.16 (0.78–1.71) .466
 Lung 2.10 (1.21–3.60) .009
 Heart 1.15 (0.63–2.07) .645
 Others (multiorgan) 0.23 (0.03–1.64) .142
Diabetes mellitus 1.95 (1.41–2.69) <.001
Medicaid/Self-pay 1.99 (1.27–3.11) .002
Abbreviations: CI, confidence interval; HR, hazard ratio.
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site of involvement was pulmonary followed by septicemia and 
skin/soft tissue involvement, similar to the clinical presentations 
reported in prior cohorts of SOT recipients [2, 3].
The majority of cases of cryptococcosis are late infections and 
considered to represent reactivation of latent infection in the 
recipient [14]. The median time to cryptococcal disease from 
transplantation in our study (464 days) was consistent with the 
findings of the TRANSNET study (575  days) [1]. Very early- 
onset of cryptococcosis (within 1 month after transplant) is rare, 
and it was reported in 5% of 175 SOT recipients with cryptococ-
cosis by Sun et al [15]. We found that 10% of SOT recipients 
were coded for very early-onset disease. Similar to the finding 
in the study by Sun et al [15], the majority of very early onset 
cryptococcal infection in our study occurred in liver and lung 
transplant recipients [15]. These very early-onset infections 
may reflect either undetected pretransplant or donor-derived 
infections. Albeit rare, this should prompt clinicians to consider 
cryptococcosis in the evaluation of very early-onset infections.
In this study, lung transplant recipients had the highest risk 
for cryptococcosis, followed by liver and heart transplant recip-
ients. Kidney transplant recipients had the lowest risk. This has 
not been reported previously in the literature. The median time 
Table 3. Cox Proportional Hazard Model of Risk Factors for Death in 42 634 Solid Organ Transplant Recipients
Univariable Analysis Multivariable Analysis
Risk Factor HR (95% CI) P HR (95% CI) P Value
Cryptococcosis  2.57 (1.89–3.50) <.001 2.29 (1.68–3.11) <.001
Cryptococcal Meningitis  2.54 (1.60–4.04) <.001
Age
 18–40 years  1.00
 41–50 years  1.46 (1.30–1.65) <.001 1.36 (1.19–1.53) <.001
 51–60 years  2.01(1.81–2.24) <.001 1.60 (1.43–1.80) <.001
 60–70 years  2.77 (2.48–3.09) <.001 2.29 (2.04–2.57) <.001
 >70 years  3.32 (2.87–3.85) <.001 3.70 (3.14–4.30)
Female sex 0.95 (0.89–1.01) .596
Type of transplant
 Kidney 1.00 1.00
 Liver 2.67 (2.47–2.87) <.001 2.47 (2.26–2.71) <.001
 Lung 4.86 (4.41–5.37) <.001 3.68 (3.28–4.12) <.001
 Heart 2.47 (2.21–2.76) <.001 2.32 (2.11–2.65) <.001
 Others (multiorgan) 3.35 (2.88–3.89) <.001 2.21 (1.86–2.65) <.001
Type of Insurance                                                                                                                                                                    > 70 years
 Medicaid/Self-pay 1.46 (1.28–1.56) <.001 1.24 (1.13–1.37) <.001
Prior transplant failure/rejection 2.66 (2.46–2.86) <.001 2.53 (2.38–2.77) <.001
Other comorbidities
 Diabetes mellitus 1.27 (1.20–1.36) <.001 1.14 (1.07–1.21) .001
 Renal failure 1.66 (1.53–1.80) <.001
 Chronic pulmonary disease 1.31 (1.20–1.44) <.001
 Obesity 1.04 (0.94–1.15) .484
 Congestive heart failure 1.68 (1.54–1.83) <.001 1.58 (1.47–1.73) <.001
 Liver disease 1.41 (1.24–1.60) <.001 1.22 (1.05–1.42) .007
 Connective tissue disorder 0.83 (0.70–0.98) .020
 Solid tumors  1.51 (1.12–2.04) .006
 Hypertension 0.52 (0.49–0.56) <.001 0.87 (0.80–0.94) <.001
 Hematological malignancies 1.65 (1.11–2.48) .013
 Cancer with metastasis 1.95 (1.27–2.99) .002
 Valvular heart disease 1.52 (1.39–1.66) <.001
 Depression 1.38 (1.26–1.52) <.001
 Pulmonary circulation disorder 2.12 (1.95–2.31) <.001
 Weight loss 2.07 (1.90–2.27) <.001 1.22 (1.11–1.34) <.001
 Peripheral vascular disease 1.34 (1.38–1.69) <.001 1.46 (1.32–1.62) <.001
 Electrolyte disorders 1.51 (1.42–1.62) <.001 1.18 (1.11–1.26) <.001
 Psychoses 1.48 (1.26–1.75) <.001 1.21 (1.02–1.42) .022
 Drug abuse 1.57 (1.33–1.81) <.001 1.20 (1.05–1.39) .006
 Neurological disorders 1.20 (1.06–1.36) .002
 Prior transplantation 1.23 (1.05–1.43) .008
Abbreviations: CI, confidence interval; HR, hazard ratio.
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to onset of cryptococcosis after transplant was earlier for lung, 
heart, and liver (<1  year) compared with kidney transplant 
recipients (1.7 years). This was similar to the findings by Husain 
et al [16], where the median time to onset of cryptococcosis was 
35 months for kidney and 25 months for heart, compared with 
8.8 and 3 months for liver and lung transplant recipients. The 
higher risk and earlier onset of disease may reflect the greater 
intensity of immunosuppression with a higher risk of reactiva-
tion disease in the nonkidney transplant populations.
Twenty-six percent of patients with cryptococcosis died 
in-hospital versus 9.1% without disease over a median follow-up 
time of 3.5  years in this large cohort of SOT recipients. The 
90-day mortality rate (13.3%) in our study was very similar to 
that reported in a multicenter study of 111 SOT recipients with 
cryptococcosis by Singh et al in the modern era of effective anti-
fungal therapy (14%) [11]. In our multivariable model, crypto-
coccosis was significantly associated with over a 2-fold increase 
risk of death. Lung, liver, and heart transplant recipients were at 
higher risk for death compared with renal transplant recipients 
after adjusting for age, cryptococcosis, and other comorbidities. 
Insurance coverage affected risk of death with patients with 
Medicaid or no health insurance at higher mortality risk.
The strengths of this study are the large cohort size, the long 
duration of follow up that allowed capture of late occurring 
infections, and identification of cryptococcosis treated in a 
hospital other than the transplant center. Twenty-six percent of 
infections were diagnosed in a hospital other than the patient’s 
primary transplant center. Use of large administrative data-
bases, such as the SID, adds to our understanding of outcomes 
of rare diseases among hospitalized patients and supplements 
detailed single- and multicenter studies. However, there are 
several limitations. The ICD-9-CM diagnosis codes used to 
identify cryptococcosis in this study have not been validated, 
although the code for cryptococcal meningitis has been used to 
describe the epidemiology of disease [17]. A validation study 
of ICD-9 diagnosis codes for several severe infections report 
positive predictive values >80% [18]. Because the study was 
limited to 3 states (California, Florida, and New York), there 
may have been regional biases introduced. Another limitation 
is that the data source used in this study contains only demo-
graphic and inpatient hospital ICD-9-CM billing data and does 
not have microbiology or other laboratory test results or data 
on antifungal or immune suppressive medications.
CONCLUSIONS
In summary, this is the first study that provides population-level 
information on the epidemiology of cryptococcosis after SOT 
in the current era. Cryptococcosis, although rare, was associ-
ated with significant mortality in this population. Lung, liver, 
and heart transplant recipients were at higher risk for crypto-
coccosis compared with kidney transplant recipients. Future 
research should focus on screening algorithms and consider 
prophylactic strategies, especially in liver and lung transplant 
recipients at risk of very early-onset disease.
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